Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cyteir Therapeutics, Inc. CYTT

Healthcare  —  Biotechnology
3.01 0.00 0.00% as of 31 May
Market cap
$108.7M
P/E
0.0×
Dividend Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Cyteir Therapeutics, Inc. (CYTT) Business Profile

Updated before January 2025

Company Overview

Cyteir Therapeutics, Inc. (NASDAQ: CYTT) is a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer and autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir focuses on advancing precision medicine by targeting DNA damage response (DDR) pathways to selectively eliminate diseased cells while sparing healthy ones. The company was co-founded by Dr. Kevin Mills, a pioneer in DDR biology, and has since grown under the leadership of a seasoned executive team. The current CEO, Markus Renschler, MD, brings extensive experience in oncology drug development, while other key leaders include Chief Scientific Officer Dr. Maurizio Voi and Chief Financial Officer Dr. Michael Mason.

Core Business Segments

Oncology Therapeutics

Cyteir’s primary focus is on developing small-molecule therapeutics targeting DDR pathways. The company’s lead product candidate, CYT-0851, is a first-in-class oral RAD51 inhibitor designed to exploit synthetic lethality in cancer cells. CYT-0851 is currently in Phase 1/2 clinical trials for hematologic malignancies and solid tumors. This innovative approach aims to selectively target cancer cells with high levels of DNA damage, minimizing off-target effects and improving patient outcomes.

Autoimmune Disease Therapies

In addition to oncology, Cyteir is exploring the application of DDR inhibitors in autoimmune diseases. By modulating the immune system’s response, the company aims to develop therapies that address the underlying causes of autoimmune disorders rather than merely managing symptoms. While this segment is in the early stages of research, it represents a promising avenue for future growth.

Research and Development Services

Cyteir also invests heavily in R&D to expand its pipeline of DDR-targeting therapies. The company collaborates with academic institutions and industry partners to accelerate the discovery and development of novel therapeutic candidates. These partnerships enable Cyteir to leverage cutting-edge technologies and expertise, ensuring a steady flow of innovative products.

Business Model

Cyteir operates on a research-driven business model, focusing on the discovery, development, and commercialization of targeted therapies. The company generates revenue primarily through licensing agreements, research collaborations, and milestone payments from partners. By maintaining a lean operational structure and outsourcing manufacturing and clinical trial activities, Cyteir minimizes overhead costs and allocates resources efficiently. This approach allows the company to concentrate on its core competencies in drug discovery and development.

Strategic Direction

Cyteir’s strategic vision centers on becoming a leader in DDR-targeting therapies. The company aims to:

  • Advance Clinical Programs: Accelerate the development of CYT-0851 and other pipeline candidates through clinical trials.
  • Expand Therapeutic Applications: Explore the potential of DDR inhibitors in autoimmune diseases and other indications.
  • Forge Strategic Partnerships: Collaborate with pharmaceutical companies and academic institutions to enhance R&D capabilities and expand market reach.
  • Achieve Sustainability Goals: Implement environmentally responsible practices in research and manufacturing processes.
  • Pursue Global Expansion: Establish a presence in key international markets to broaden access to its therapies.

Competitive Landscape

Cyteir operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • AstraZeneca: A leader in DDR-targeting therapies with its PARP inhibitors, such as Lynparza.
  • GlaxoSmithKline (GSK): Actively developing DDR inhibitors for oncology and other indications.
  • Repare Therapeutics: Focused on synthetic lethality-based therapies for cancer.
  • Zentalis Pharmaceuticals: Developing small-molecule therapeutics targeting DDR pathways.

Despite the competition, Cyteir differentiates itself through its unique approach to targeting RAD51 and its focus on both oncology and autoimmune diseases.

Risk Factors

Cyteir faces several risks that could impact its operations and financial performance:

  • Clinical Trial Risks: The success of CYT-0851 and other candidates depends on positive clinical trial outcomes, which are inherently uncertain.
  • Regulatory Challenges: Obtaining regulatory approval for new therapies is a complex and time-consuming process.
  • Market Dependence: The company’s revenue is heavily reliant on the success of its lead product candidate.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers exposes Cyteir to potential delays and quality issues.
  • Competitive Pressure: The biotechnology sector is highly competitive, with rapid advancements in technology and science.

Recent Developments

In 2023, Cyteir announced promising interim results from its Phase 1/2 clinical trials of CYT-0851, demonstrating favorable safety and efficacy profiles in patients with advanced cancers. The company also entered into a strategic collaboration with a leading academic institution to explore the application of DDR inhibitors in autoimmune diseases. Additionally, Cyteir expanded its intellectual property portfolio by securing patents for its RAD51 inhibitors, strengthening its competitive position.

Global developments, such as the COVID-19 pandemic, have posed challenges to clinical trial timelines and supply chain operations. However, Cyteir has implemented contingency plans to mitigate these impacts and ensure continuity in its R&D activities.

Investment Considerations

Strengths

  • Innovative Pipeline: A robust pipeline of DDR-targeting therapies with significant market potential.
  • Experienced Leadership: A management team with deep expertise in oncology and drug development.
  • Strategic Partnerships: Collaborations with academic and industry partners enhance R&D capabilities.
  • Strong IP Portfolio: Patents for RAD51 inhibitors provide a competitive edge.

Risks

  • Early-Stage Company: As a clinical-stage biotech, Cyteir has no approved products and relies on external funding.
  • Regulatory Uncertainty: The approval process for new therapies is complex and uncertain.
  • Market Competition: Intense competition from established players and emerging biotech firms.

Conclusion

Cyteir Therapeutics, Inc. is at the forefront of developing innovative therapies targeting DDR pathways. With a promising pipeline, experienced leadership, and strategic partnerships, the company is well-positioned to address unmet medical needs in oncology and autoimmune diseases. While challenges remain, Cyteir’s focus on precision medicine and its commitment to advancing science make it a compelling player in the biotechnology sector. As the company progresses through clinical trials and expands its pipeline, it has the potential to deliver significant value to patients and investors alike.